Screener
CRISPR Therapeutics CRSP Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -15,754.2%-14,495pp | -18,933.6%-17,683pp | -1,498.3%— | -1,451.9%— | -1,259.2%— | |
| Net margin | -13,856.5%-12,833pp | -16,569.8%-15,588pp | -1,273.7%— | -1,229.4%— | -1,023.6%— | |
| Returns | ||||||
| Return on equity | -31.2%-11.5pp | -30.2%-11.0pp | -25.3%— | -25.3%— | -19.7%— | |
| Return on invested capital | -32.4%-4.7pp | -36.5%-10.5pp | -30.4%— | -31.9%— | -27.7%— | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×-0.1× | 0×-0.1× | 0×-0.1× | |
| Liquidity | ||||||
| Current ratio | 18×+2.3× | 13.3×-8.8× | 16.2×-5.4× | 16.6×+0.9× | 15.6×-2.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×+0.3× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $18.89-11.2% | $21.37-6.7% | $20.98-7.8% | $19.65-15.8% | $21.28-16.5% | |
| Valuation | ||||||
| Market capitalization | $5.36B-19.1% | $5B+48.8% | $5.89B+47.3% | $4.04B-11.9% | $2.92B-46.7% | |
| Price / sales | 1,306.5×+1,134× | 1,423.8×+1,334× | 153.8×+134× | 106.2×+83.5× | 77.5×+57.3× | |
| Price / book | 3×-0.5× | 2.6×+0.9× | 3.1×+1.0× | 2.4×0.0× | 1.6×-1.0× |
FAQ
- Where do CRISPR Therapeutics's ratios come from?
- Every ratio is computed from CRISPR Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
